Scarica l'app Stockscreener
35.65
1.05%
0.37
Dopo l'orario di chiusura:
35.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$35.28
Aprire:
$35.68
Volume 24 ore:
1.04M
Relative Volume:
1.08
Capitalizzazione di mercato:
$2.80B
Reddito:
$866.00K
Utile/perdita netta:
$-283.65M
Rapporto P/E:
-8.3548
EPS:
-4.267
Flusso di cassa netto:
$-226.25M
1 W Prestazione:
+0.65%
1M Prestazione:
+1.11%
6M Prestazione:
+35.91%
1 anno Prestazione:
+52.68%
Intervallo 1D:
$35.12
$36.40
Intervallo di 1 settimana:
$33.37
$36.40
Portata 52W:
$19.72
$40.30
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Nome
Celldex Therapeutics Inc
Settore
Industria
Telefono
908-200-7500
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
35.65 | 2.77B | 866.00K | -283.65M | -226.25M | -4.267 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Aggiornamento | Barclays | Underweight → Overweight |
| 2026-03-23 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-13 | Iniziato | Barclays | Underweight |
| 2025-04-28 | Iniziato | Canaccord Genuity | Buy |
| 2025-03-20 | Iniziato | Morgan Stanley | Overweight |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-10-07 | Iniziato | Citigroup | Buy |
| 2024-09-30 | Iniziato | Goldman | Neutral |
| 2024-09-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Iniziato | Stifel | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2023-12-20 | Iniziato | TD Cowen | Outperform |
| 2023-11-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Iniziato | Wells Fargo | Underweight |
| 2021-09-17 | Iniziato | Jefferies | Buy |
| 2021-09-10 | Iniziato | SVB Leerink | Outperform |
| 2021-07-22 | Iniziato | Guggenheim | Buy |
| 2020-02-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-07 | Iniziato | Aegis Capital | Buy |
| 2016-03-08 | Downgrade | Jefferies | Buy → Hold |
| 2016-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2016-03-07 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-01 | Iniziato | H.C. Wainwright | Buy |
| 2015-08-11 | Reiterato | Brean Capital | Buy |
| 2015-08-11 | Reiterato | Oppenheimer | Outperform |
| 2015-08-11 | Reiterato | ROTH Capital | Buy |
| 2015-06-02 | Reiterato | WBB Securities | Strong Buy |
| 2014-11-17 | Reiterato | ROTH Capital | Buy |
| 2014-03-04 | Reiterato | Oppenheimer | Outperform |
| 2013-07-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-03-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-02-26 | Reiterato | Oppenheimer | Outperform |
| 2013-01-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2012-10-02 | Reiterato | Oppenheimer | Outperform |
| 2012-09-14 | Reiterato | Cantor Fitzgerald | Buy |
Mostra tutto
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
Celldex Therapeutics Inc (CLDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Celldex Therapeutics Inc (CLDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts (NASDAQ:CLDX) - Seeking Alpha
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celldex Therapeutics, Inc. Revenue Breakdown – DUS:TCE2 - TradingView
CLDX|Celldex Therapeutics Inc|Price:35.280|Chg%:-0.140 - TradingKey
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year? - Yahoo Finance
Celldex Therapeutics (CLDX) Stock May Trade At A Premium After A 59% Run - Sahm
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $40 to $70 - Moomoo
Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Bristol-Myers Squibb (BMY) and Peptidream (OtherPPTDF) - The Globe and Mail
CELLDEX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $70 FROM $78 - webull.com
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial DiscontinuationSlideshow (NASDAQ:CLDX) 2026-07-22 - Seeking Alpha
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study - BioPharma Dive
Drum KIT: Celldex CSU rhythm still on post-barzo PN phase II - BioWorld News
Stifel Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $68 - Moomoo
Celldex cuts price target after halting Phase 2 trial for key drug due to efficacy failure. - Pluang
Celldex Stands By Barzolvolimab in CSU After Prurigo Nodularis Miss - insights.citeline.com
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower - Benzinga
Canaccord cuts Celldex stock price target after trial miss By Investing.com - Investing.com Canada
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study - Benzinga
Celldex scraps antibody in itchy skin nodules after Phase 2 flop - Endpoints News
Celldex drops Phase II study of barzolvolimab in prurigo nodularis - The Pharma Letter
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss - Yahoo Finance
Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating - marketscreener.com
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
CLDX Stock Down 10% After-Hours — What’s Driving The Selloff? - Yahoo Finance
Celldex discontinues prurigo nodularis trial after phase 2 miss - Investing.com
Celldex stock falls after phase 2 trial misses key endpoints By Investing.com - Investing.com Canada
Celldex discontinues prurigo nodularis trial after phase 2 miss By Investing.com - Investing.com Canada
Celldex stock falls after phase 2 trial misses key endpoints - Investing.com
Celldex Drug Depleted Mast Cells but Did Not Ease PN Itch - Stock Titan
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: A Biotech Gem with 64% Potential Upside - DirectorsTalk Interviews
Guggenheim raises Celldex stock price target on trial outlook By Investing.com - Investing.com Canada
MSN Money - msn.com
Celldex Therapeutics, Inc. Announces Retirement of Sam Martin from Senior Vice President, Effective on or About March 31, 2027 - marketscreener.com
Celldex Therapeutics, Inc. Announces Retirement of Sam Martin as Chief Financial Officer, Effective on or About March 31, 2027 - marketscreener.com
Celldex Therapeutics CFO Plans to Retire in 2027 - marketscreener.com
Celldex CFO Sam Martin to retire in March 2027 By Investing.com - Investing.com Canada
Celldex CFO Sam Martin to Retire; Company Begins Search for Successor - TradingView
Celldex CFO Sam Martin to retire in March 2027 - Investing.com
Celldex Therapeutics (NASDAQ: CLDX) CFO to retire around March 2027 - Stock Titan
Celldex Starts CFO Search as Martin Plans 2027 Retirement - Stock Titan
Press Release: Celldex Announces Planned Transition of Chief Financial Officer - Moomoo
Celldex Therapeutics (CLDX) Gets Fresh Index Attention As Valuation Debate Heats Up - simplywall.st
Celldex Therapeutics stock hits 52-week high at 39.16 USD By Investing.com - Investing.com Nigeria
Celldex Therapeutics stock hits 52-week high at 39.16 USD - Investing.com
Price to sales forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Price to book forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed? - Sahm
Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):